1. INTRODUCTION {#sec1}
===============

There is convincing evidence that the world is faced with an increased prevalence of hypertension (HTN) \[[@r1]\]. 31% of the world's adults had HTN in 2010 \[[@r2]\] (Mills, *et al*. 2015). HTN is a worldwide health problem and the most important factor in increasing the burden of disease in the world \[[@r3], [@r4]\]. Among the 25 factors leading to disability, HTN (HTN) was ranked fourth in 1990 and then ranked as the first factor in 2010 \[[@r5]\].

HTN is associated with a high incidence of debilitating complications, such as stroke, heart attacks, and renal failure, which impose a large economic burden on society. For example, estimates indicate that 54-6.64% of stroke and 47% of coronary heart disease worldwide are due to HTN \[[@r6], [@r7]\]. Findings revealed that HTN increases the risk of dementia \[[@r8], [@r9]\] and depression \[[@r10]\] in the elderly. Worldwide, costs to treat HTN and its consequences are substantial. For instance, it is predicted that the future cost of cardiovascular complications caused by HTN in the United States would be raised 238% from 2010 to 2030 \[[@r11]\].

The prevalence of HTN varies across the world considerably. Its prevalence was 39.1% in Latin America, 26.9% in the Middle East and North Africa, 29.4% in South Asia, 31.5% in European and Central Asia countries, 31.1% in Sub-Saharan Africa, and 35.7% in East China and the pacific \[[@r12]\]. The results of a meta-analysis study in 2012 indicated that the prevalence of HTN in China was 21.5% \[[@r13]\]. In Iran, two meta-analyses have been conducted related to the prevalence of HTN in 2008 and 2012. According to the first study, the prevalence of HTN in the 30-55 age group and older than 55 years, were 23% and 50%, respectively \[[@r14]\]. In 2012, the prevalence of HTN in adults was 22% \[[@r15]\]. In addition, various studies have been carried out on the prevalence of HTN in different parts of Iran which reported different rates \[[@r16]-[@r18]\]. Evidence suggests that in developing countries such as Iran, better care and more effective disease treatment has increased life expectancy that followed by increasing of elderly population; consequently raising of the elderly population leads to an increase in the prevalence of HTN \[[@r19], [@r20]\].

The prevalence of HTN can be affected by demographic factors, such as age, race, gender, and socio-economic status \[[@r21]\]. Iran is a large country in the eastern half of the Middle East with approximately 70 million people with different ethnicities. Ethnic diversity in Iran results in very different cultures, lifestyles, and socioeconomic status that may affect individuals' blood pressure. This study aimed to estimate an overall prevalence of HTN in Iran and provide more current estimates.

2. METHODOLOGY {#sec2}
==============

The protocol of this review has been registered in the International prospective register of systematic reviews (PROSPERO) with the number of CRD42017068574.

2.1. Search Strategy {#sec2.1}
--------------------

This systematic and meta-analysis of HTN in Iranian society was reviewed based on studies published in national and international journals between 2004 and 2018. We used the following databases: Magiran, Iran Medex, the Iranian Archive for Scientific Documents Center (IASD), the Iranian National Library (INL), Medline (PubMed, Ovid), Scopus, Web of Science Embase. Google Scholar and Google were used as a search engine. Also, grey literature was examined for related articles. The keywords including "systolic", "diastolic", "blood pressure", " hypertension", "white coat HTN", "Iran", "prevalence", and combinations of these using Boolean operators and "\*" were used to search for primary studies. Given the definition of blood pressure by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7), which determined HTN as BP ≥ 140/90 \[[@r22]\]; so our criteria of HTN in analyzed studies were SBP ≥140 mm Hg and DBP ≥90 mm Hg. The screening and selection process was conducted according to PRISMA guidelines \[[@r23]\].

2.2. Selection of Studies and Data Extraction {#sec2.2}
---------------------------------------------

All observational (non-interventional) studies that referred to the frequency or prevalence of HTN in Iranian society were included in the study. Exclusion criteria were related to the interventional studies, letters to the editor, studies on pregnant women and children, and studies with poor methodological quality. Also, studies without keywords of blood pressure, HTN, Iran, systolic, diastolic, and prevalence were excluded. For some articles which were published in both Persian and English language, we analyzed the one with more detailed data. For data extraction, the form we used included the variables of the first author of the studies, year of publication, setting, total sample size, sample size in men and women, number of patients with HTN in general and by sex. According to inclusion and exclusion criteria, titles and abstracts of primary studies were independently assessed by two researchers and for related articles, the full texts were extracted and assessed. In case of disagreement between the two researchers, the article was assessed by the third author who was an expert in the meta-analysis.

2.3. Evaluation and Review Articles {#sec2.3}
-----------------------------------

To assess the quality of the primary studies, we used a standard tool which has been applied in various internal and external studies \[[@r24]-[@r27]\]. The quality assessment form of the studies included 5 items including research design, sampling method, comparison group, sample size, instrumental psychometric properties. Each item was ranked from 0 to 3 and its overall score ranged from (0 to 15). Accordingly, the studies were divided into three groups: weak (0 to 5), moderate (5-10) and strong (10 up) \[[@r26]\]. The quality of the studies was investigated by two researchers (M.J. and R.G.) and the differences were resolved by the third author (F.M). All studies had moderate to high quality, then all of them were entered to the analysis.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Regarding the prevalence rate with a binomial distribution, the variance of each research was calculated through binomial distribution variance. The weighted average was used to combine the prevalence rates of the studies. The weight assigned to each study was the inverse of its variance. The I2 index was used to examine the heterogeneity of data. Heterogeneity of data was divided into three classes of less than 25% (low heterogeneity), 25% to 75% (moderate heterogeneity) and over 75% (high heterogeneity). Given the high heterogeneity of the data, the random effects model was used. Subgroup analysis was performed based on gender, age, type of study and population. To assess trends of prevalence of HTN from 2004 to 2017, we categorized primary studies based on the study conducted time into four period time of 2004-2006, 2007-2009, 2010-2012, and 2013-2017. The increase in the period of 2013-2017 was due to the low number of primary articles. Meta-regression method was used to investigate the correlation between the prevalence of HTN and the year of study, and the number of samples. Publication bias was assessed with the Egger test. Data analysis was done with STATA 12 software.

3. RESULTS {#sec3}
==========

In this study, all studies related to the prevalence of blood pressure in Iranian society from 2004 to 2017, were systematically assessed according to the PRISMA guidelines (Fig. **[1](#f1){ref-type="fig"}**).

In the initial search, 1123 papers were identified, which eventually led to 58 eligible studies entered to the final analysis. The total sample size was 902,580 subjects with an average of 15743 per study. The lowest and highest sample sizes were related to Akbarzadeh (2009) \[[@r28]\] and Faramarzi (2009) \[[@r29]\] respectively. 52 of the studies were cross-sectional, and five were cohort studies. The characteristics of the articles are presented in Table **[1](#t1){ref-type="table"}**.

The findings showed that the overall prevalence of HTN in Iranian society was 25% (95% CI: 22 - 28%). The prevalence of HTN in cross-sectional studies (27% with a 95% CI of 23-30) was more than cohort studies (22% with 95% CI of 11 - 33). The findings also showed that the prevalence of HTN in older adults was higher than other age groups (42% with 95% CI: 22-62), the prevalence of HTN was 25% (95% CI: 19-31) in women and 24% (95% CI: 20-28) in men, with no significant difference (p = 0.758). The findings showed that the highest and the lowest prevalence of HTN were in Region 3 (East Azarbaijan, West Azarbaijan, Ardebil, Zanjan, Guilan and Kurdistan provinces) and region 2 (Isfahan, Fars, Bushehr, Chaharmahal Bakhtiari, Hormozgan and Kohkiloyeh and Boyerahmad provinces) (33% versus 22%), respectively. Further details of the prevalence of HTN in the subgroups are presented in Table **[2](#t2){ref-type="table"}**. The pooled prevalence of HTN is shown in Fig. **[2](#f2){ref-type="fig"}**.

The trend of prevalence of HTN in Iran, from 2004 to 2017 is shown in Table **[3](#t3){ref-type="table"}**. The prevalence of HTN in Iran was not significantly correlated with the year (p = 0.708), and sample size (p = 769), but In relation to the mean age of the samples, showed a significant correlation (p = 0.003) (Fig. **[3](#f3){ref-type="fig"}**). According to Fig. **[4](#f4){ref-type="fig"}**, the results of the Egger test showed that the bias of publication of the preliminary studies is not significant (p = 0.172).

4. DISCUSSION {#sec4}
=============

In our systematic and meta-analytical review, 58 primary articles were investigated to estimate the overall prevalence of HTN in Iran. This study covers all areas of Iran with 31 provinces. All data were collected from 2004 to 2017. A systematic study related to the prevalence of HTN in Iran has not been conducted recently, and the latest related study was done around 5 years ago \[[@r15]\]. Because the findings of the present study are based on a large number of primary studies, our study can be fitted to the needs of health providers.

The overall prevalence of HTN in Iran was 25%, which was different in cross-sectional and cohort studies, with a prevalence of 26% and 22%, respectively. Among the 51 European countries in 2014, the minimum and maximum prevalence of HTN were related to the United Kingdom (15.2%) and Estonia (31.7%) \[[@r30]\]. Analyzing studies until 2015 in low- and middle-income countries, have shownthat the overall prevalence of HTN was 32.3% \[[@r12]\].

Comparison of the results shows the prevalence of HTN in different countries varies, however, remains approximately near to each other. Variations in the reported prevalence in several countries can be due to genetic and environmental factors (like exercising), also it can be due to the heterogeneity of research methods and the rate of controlling of variables like age and sex in studies.

To study more accurately of the prevalence of HTN in Iran, the trend of prevalence of HTN was assessed from 2004 to 2017. The finding showed nearly a similar trend of prevalence of HTN during periods of 2004-2006, 2007 to 2009, and 2013 to 2017. Through the period from 2010 to 2012, the prevalence of HTN was lower than others. The major source of the low prevalence of HTN in this period of time could be related to the three primary studies \[[@r31], [@r32]\] that with a very low prevalence of HTN (below th 0.07) which has had a descending impact on the total prevalence of HTN over this period. Two of these three studies were conducted by Mahram *et al*. \[[@r31]\]{Mahram, 2013 \#2724}, with population age of 30-60 years-old and the third one conducted by Mojahid *et al*. \[[@r32]\], with young people with the age of 20-29. It seems that the most important factor in reducing the prevalence of HTN in these three studies and subsequently in the period time of 2010 to 2012 was ages of subjects. Because the prevalence of HTN is directly related to age and all the samples studied in these three studies were young and adult. While other studies, in addition to low age groups, included elderly population too. By excluding of these three studies and re-analyzing, the prevalence of HTN was equal to other periods. Assessing the trend of prevalence of HTN shows that, the prevalence of HTN has not diminished versus progress and development in people\'s lives, and its rate has been roughly the same throughout 2004-2017. in Iran, comparing the results of previous same studies with the result of our study showed that the overall prevalence of HTN is increasing (25% versus 23% and 21%) \[[@r14], [@r15]\]. the prevalence of HTN in the United States and China was 28% \[[@r33]\] and 27% \[[@r34]\] in 2009 and 2007 which are lower than the recently reported prevalence of 29% \[[@r1]\] and 35/7% \[[@r12]\], respectively.

Considering the trend of prevalence of HTN over periods of years from 2004 to 2017 and increasing of overall prevalence of HTN in recent studies comparing to the past ones, it can found that with the advancement of technology, treatment, care and disease prevention, over the time, decreasing of the prevalence of HTN has not happened. A possible explanation of this trend of HTN may be related to economic development, urbanization, aging of population, lifestyle changes, bad diet and environmental degradation. In addition, an increase in obesity and overweight, lipid disorders, high salt intake, smoking, sedentary and inadequate lifestyle can also are exacerbating factors \[[@r13]\].

Because of the high heterogeneity in the primary studies, the prevalence of HTN was estimated based on sub-group analysis.

Subgroup analysis results showed that the elderly group has the highest prevalence of HTN (42%) compared to other groups, which is consistent with other studies like the United States with 63.1% \[[@r1]\], previous meta-analysis in Iran with 50% \[[@r14]\], and low- and middle-income countries with 65.6% \[[@r12]\]. The high prevalence of HTN in the elderly can be attributed to various factors such as atherosclerosis and their underlying conditions \[[@r35]\].

After the elderly group, drivers had the most prevalence of HTN. In this case, we can say that half of the drivers are at the pre-hypertensive stage and most of them were overweight and obese in Iran \[[@r36]\]. The lack of attention to health issues in this group has led them to suffer from HTN. The cause of overweight in the drivers may be because of the use of restaurant fatty foods and the lack of information on their diet and inactivity with being in more sitting position.

In the present study, the prevalence of HTN in men was slightly higher than women. However, this difference was not statistically significant and is consistent with other studies \[[@r12], [@r30], [@r33], [@r37], [@r38]\]. The reason for this difference may be that that middle-aged men are prone to cardiovascular disease \[[@r12]\]. Also, in Iran, Men are more likely to work outside the home with a stressful situation compared women and they are less concerned about their self-care, taking anti-hypertensive medications, and doing exercise, which could lead to an increased prevalence of HTN in them \[[@r39]\]. However, in the United States and the Netherlands, HTN was reported more frequently in women than men \[[@r34]\]. In Yemen, as a low-income country, HTN was slightly higher in women than in men (14.8% versus 14.2%) \[[@r40]\]. Nonetheless, the high prevalence of HTN in women, as compared to men, may be due to a higher BMI, lifestyle and menopause period \[[@r41]\].

The findings showed that the third region (provinces of East Azarbaijan, West Azarbaijan, Ardebil, Zanjan, Gilan and Kurdistan) and the second region (provinces of Tehran, Alborz, Qazvin, Mazandaran, Semnan, Golestan and Qom) have the highest and lowest incidence of HTN, respectively. Results of related studies with regard to the area of residence and size of cities and its relation to the prevalence of HTN indicated that cities with the average size compared to small size, had the highest prevalence of HTN (24.6% versus 20.6%) and large cities also had the lowest prevalence of HTN (18.9%) \[[@r42]\]. A study by Adeloye *et al*. showed that the prevalence of HTN in rural areas was lower than in urban areas (31% versus 26%) \[[@r43]\]. Also in African countries, the prevalence of HTN was even more among urban residents \[[@r43]\]. The higher prevalence of HTN among the third region populations may be due to their different lifestyle patterns. Factors such as lack of mobility, air pollution, industrial stress, fast food and high fat and high-fat diet could increase the prevalence of HTN in industrial cities compared to semi-industrial cities and rural areas \[[@r44]\]. However, the results of some studies also indicated an increased prevalence of HTN in marginal and rural areas \[[@r45]\]. The possible reason for this could be that, although the rural areas are a stress-free environment for living, a low level of health literacy, less access to health centers, and educational facilities could lead to increased prevalence of HTN. In addition of environmental and lifestyle characteristics which are different in five regions of Iran and could effect on HTN prevalence ratio, also the study characteristics, such as the type of sampling, the age of the population studied, the amount of knowledge and experience of the researchers in the correct guidance of the study could also influence the difference of the prevalence in the different regions.

According to our meta-regression results, the prevalence of HTN in Iran was not significantly different based on year of study and sample size, except age. A study in China showed that, the prevalence of HTN in the years 2011-2007 was nearly similar in the years of 2006-2002 (20.6% *vs*. 21.9%) (13). Also, our meta-regression result indicated that with aging, the prevalence of HTN is increasing significantly, which is in line with previous studies \[[@r1], [@r12], [@r30]\].

CONCLUSION
==========

The current prevalence of HTN is high and its trend over time, has been fixed without a reduction in Iran. There were differences in the prevalence of HTN and variables such as age, gender, population. Older adults as compared to other population groups have the highest rate of prevalence. The reasons for not reducing the prevalence of HTN should be investigated and strategies for controlling and reducing it should be planned.

One of the most important limitations of this study was the lack of adequate information reported by some studies. However, the study has strengths of covering more databases and comprehensive reviews made it possible to access the majority of related primary studies.
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###### Characteristics of the final papers entered in the analysis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Row**   **First Authour**            **Study Design**   **Year**   **Sample**\   **Setting**        **Target Population**               **Prevalence (%)**   **Language**
                                                                       **Size**                                                                                  
  --------- ---------------------------- ------------------ ---------- ------------- ------------------ ----------------------------------- -------------------- --------------
  1         Ghanbariyan *et al*.         Cross-sectional    2004       8491          Tehran             Adults                              22                   Persian

  2         Taraghi *et al*.             Cross -sectional   2004       122           Sari               Adult drivers                       36.9                 Persian

  3         Godarzi *et al*.             Cross -sectional   2005       1530          Zabul              Adults                              13.9                 Persian

  4         Delavari *et al*.            Cross- sectional   2005       24525         national project   Adults                              30.5                 Persian

  5         Delavari *et al*.            Cross -sectional   2005       13033         national project   Adults                              29.2                 Persian

  6         Yousefinejad *et al*.        Cross-sectional    2006       1854          Sanandaj           Adults with blood transfering       3.4                  Persian

  7         Sharifi rad *et al*.         Cross- sectional   2007       255           Esfahan            elderly                             46.7                 Persian

  8         Delavari *et al*.            Cross- sectional   2007       75112         national project   Adults                              30.2                 Persian

  9         Rafiee *et al*.              Cross -sectional   2007       458           Arak               Postmenopausal women                65.5                 Persian

  10        Dabbaghmanesh *et al*.       Cross-sectional    2008       3245          Shiraz             Adults                              27.5                 Persian

  11        Esteghamati *et al*.         Cross -sectional   2008       68250         national project   Adults                              32                   English

  12        Esteghamati *et al*.         Cross -sectional   2009       5287          national project   Adults                              26.6                 English

  13        Mardani *et al*.             Cross -sectional   2009       340           Arak               Adults                              13.5                 Persian

  14        Akbarzadeh *et al*.          Cross-sectional    2009       107           Shiraz             Adult women                         12.15                Persian

  15        Akbarzdseh *et al*.          Cross-sectional    2009       107           Shiraz             Adult women                         3.7                  Persian

  16        Amirkizi *et al*.            Cross-sectional    2009       370           Kerman             Women with reproductive age         14.3                 Persian

  17        Faramarzi *et al*.           Cross -sectional   2009       447251        Shiraz             Adults                              21                   Persian

  18        Ramazani *et al*.            Cross sectional    2009       3670          Esfahan            Adults                              20.7                 English

  19        Neghab *et al*.              Cohort             2009       140           Shiraz             Petrochemical personnel             20                   English

  20        Neghab *et al*.              Cohort             2009       140           Shiraz             Petrochemical personnel             12.8                 English

  21        Veghari *et al*.             Cross -sectional   2010       2497          Golestan           Adults                              23.9                 Persian

  22        Sahebi *et al*.              Cross-sectional    2010       1027          Shiraz             Hospital staff                      37                   English

  23        Kasai *et al*.               Cross -sectional   2010       1000          Zanjan             Adults                              27.8                 English

  24        Ebrahimi *et al*.            Cross -sectional   2010       30000         National project   Adults                              17.3                 English

  25        Sharifi *et al*.             Cross- sectional   2010       266           Tehran             Elderly                             61                   English

  26        Damrchi *et al*.             Cross -sectional   2010       1218          Tehran             Drivers                             35.4                 Persian

  27        Kalani *et al*.              Cross -sectional   2011       1130          Yazd               Adults                              38.1                 Persian

  28        Ghazanfari *et al*.          Cross- sectional   2011       400           Kerman             Adults                              23.8                 Persian

  29        Saharki *et al*.             Cross-sectional    2011       2300          Zahedan            Adults                              27                   English

  30        Abtahi *et al*.              Cross-sectional    2011       3115          Shiraz             Teachers                            18.2                 English

  31        Namayandeh *et al*.          Cross-sectional    2011       2000          Yazd               Adults                              42.5                 English

  32        Khosh andam *et al*.         Cross-sectional    2011       400           Mazandaran         Drivers                             20                   Persian

  33        Peyman *et al*.              Cross-sectional    2012       121           Ilam               Elderly                             36.8                 Persian

  34        Moeni *et al*.               Cross-sectional    2012       2063          Esfahan            Elderly with heart disease          4                    English

  35        Ghari poor *et al*.          Cross sectional    2012       975           Esfahan            Adults                              18.9                 English

  36        Barikani *et al*.            Cross-sectional    2012       328           Ghazvin            women Adults                        32                   English

  37        Maracy *et al*.              Cross sectional    2012       3000          Esfahan            Adults                              22.2                 English

  38        Rezaiean *et al*.            Cross-sectional    2012       445           Hamadan            Kidney patients                     22.2                 English

  39        Mahram *et al*.              Cross-sectional    2013       5231          Ghazvin            Water-containing arsenic consumer   7                    English

  40        Mahram *et al*.              Cross-sectional    2013       9838          Ghazvin            Above control group                 3.7                  English

  41        Malek Zadeh *et al*.         Cross-sectional    2013       50045         Gholston           Adults                              42.7                 English

  42        Ahmadi *et al*.              Cohort             2014       2570          Tehran             Patient with rectum cancer          13.4                 English

  43        Safari Moradabadi *et al*.   Cross sectional    2014       1531          Bandar abas        Adults                              35.3                 Persian

  44        Chraghian *et al*.           Cross sectional    2014       69173         Tehran             Adults                              5.3                  English

  45        Najafi poor *et al*.         Cross sectional    2014       5900                             Adults                              18.4                 English

  46        Talayi *et al*.              Cohort             2014       3283          Esfahan            Adults                              25.4                 English

  47        Kalani *et al*.              Cross-sectional    2015       1130          Yazd               Adults                              38.1                 English

  48        Yazdan panah *et al*.        Cross -sectional   2015       944           Ahvaz              Adults                              17.6                 English

  49        Poorolajal *et al*.          Cross -sectional   2015       7611          Tehran             Clinical patients                   9.1                  English

  50        Chraghi *et al*.             Cross- sectional   2016       476           Bahar              elderly                             25                   Persian

  51        Gerayloo *et al*.            Cross-sectional    2016       227           Moraveh tapeh      Employees                           8.3                  Persian

  52        Mojahedi *et al*.            Cross-sectional    2016       3608          Mashad             youngs                              1.4                  Persian

  53        Esteghamati *et al*.         Cross- sectional   2016       8218          national project   Adults                              25.6                 English

  54        Ghaffari *et al*.            Cross -sectional   2016       1071          Tabriz             elderly                             68                   English

  55        Jamshidi *et al*.            Cross -sectional   2017       321           Hamadan            elderly                             16.2                 English

  56        Ebrahimi *et al*.            Cross-sectional    2014       9762          Mashhad            Adults                              23                   English

  57        Khajedaluee ***et al*.**     Cross-sectional    2016       2974          Mashhad            Adults                              22                   English

  58        Khosravi *et al*.            Cohort             2013       5190          Shahroud           Adults                              38.2                 English
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Table **1**. Selected articles for meta-analysis of hypertension in Iran 2004-2017.

###### Prevalence of HTN based on subgroup.

  **Variable**        **Categories**    **Number of Studies**   **Sample Size**   **Prevalence (%)**   **Confidence Interval 95%**   **Hetrogenicity**   
  ------------------- ----------------- ----------------------- ----------------- -------------------- ----------------------------- ------------------- --------
  Type of study       Cross sectional   52                      898598            26                   23-30                         99.9                0.0001
  Cohort              5                 6374                    22                7-21                 97.6                          0.0001              
  Language of study   English           28                      3510              25                   19-29                         99.9                0.0001
  Persian             21                362495                  24                21-31                99.9                          0.0001              
  Population          Drivers           3                       1740              31                   19-42                         95.3                0.0001
  Patients            4                 15081                   12                -4)-60)              100                           0.0001              
  Women               5                 1370                    26                3-47                 99.2                          0.0001              
  Elderly             6                 2510                    42                22-62                99.2                          0.0001              
  Adults              40                904972                  24                18-26                99.9                          0.0001              
  Gender              Male              23                      404580            24                   20-28                         99.9                0.0001
  Female              23                383542                  25                19-31                99.9                          0.0001              
  Region              Region1           15                      200736            24                   14-30                         100                 0.0001
  Region2             15                472301                  22                16-36                99.9                          0.0001              
  Region3             3                 3925                    33                (-5)-72              99.9                          0.0001              
  Region4             7                 3105                    28                15-40                98.9                          0.0001              
  Region5             11                31104                   24                14-33                99.8                          0.0001              
  Unknown             7                 162995                  27                23-31                99.9                          0.0001              

Region 1: Provinces of Tehran, Alborz, Qazvin, Mazandaran, Semnan, Golestan and Qom; Region 2: Isfahan, Fars, Bushehr, Chaharmahal Bakhtiari, Hormozgan and Kohkiloyeh and Boyerahmad provinces; Region 3: East Azarbaijan, West Azarbaijan, Ardebil, Zanjan, Gilan and Kurdistan; District 4: Kermanshah, Ilam, Lorestan, Hamedan, Central and Khuzestan provinces; District 5: Khorasan Razavi, Southern Khorasan, Northern Khorasan, Kerman, Yazd and Sistan and Baluchestan provinces.

###### Trend of prevalence of hypertension from 2004 to 2017 in Iran.

  **Years**       **Number of Studies**   **Prevalence (%)**
  --------------- ----------------------- --------------------
  **2004-2006**   14                      26
  **2007-2009**   25                      26
  **2010-2012**   11                      22
  **2013-2017**   8                       26
